Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

273
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
273
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

373
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
373

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning-based prediction of mortality and hospitalization in diabetic patients with heart failure with preserved ejection fraction: the GUARDIAN-P risk score.

European heart journal. Digital health·2026
Same author

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same author

An autopsy-based study on child mortality under six in Taiwan: Forensic autopsy findings and the complexities of causal determination.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Cortical Microinfarcts Are Related to Amyloid Pathology and Cognitive Decline in Spontaneous Intracerebral Hemorrhage.

Journal of stroke·2026
Same author

Aldosterone-targeted Therapy after Primary Aldosteronism Testing in Resistant Hypertension: A Nationwide Cohort Study.

medRxiv : the preprint server for health sciences·2026
Same author

Erratum. Unilateral Primary Aldosteronism Lacking KCNJ5 Somatic Mutations Is Associated With an Elevated Risk of New-Onset Diabetes. Diabetes 2025;74:850-859.

Diabetes·2026

Related Experiment Video

Updated: May 7, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

23.2K

The Captopril Challenge Test Predicts Cardiac Structure and Dysfunction in Primary Aldosteronism.

Uei-Lin Chen1,2,3, Che-Wei Liao4, Shuo-Meng Wang5

  • 1Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City 100229, Taiwan.

The Journal of Clinical Endocrinology and Metabolism
|January 2, 2025
PubMed
Summary
This summary is machine-generated.

The captopril challenge test (CCT) reveals aldosterone levels linked to heart issues in primary aldosteronism (PA). Higher post-CCT aldosterone predicts worse cardiac remodeling but also greater treatment improvement.

Keywords:
aldosteronecaptopril suppression testdiastolic dysfunctionleft ventricular remodelingprimary aldosteronism

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.3K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

15.6K

Related Experiment Videos

Last Updated: May 7, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

23.2K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.3K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

15.6K

Area of Science:

  • Cardiology
  • Endocrinology
  • Medical Diagnostics

Background:

  • The captopril challenge test (CCT) assesses aldosterone production in primary aldosteronism (PA).
  • It helps determine the magnitude of renin- and angiotensin II-independent aldosterone production.
  • This aids in identifying the presence and severity of PA.

Purpose of the Study:

  • To investigate the association between post-CCT plasma aldosterone concentration (PAC) and cardiovascular remodeling.
  • To examine the link between post-CCT PAC and diastolic dysfunction.
  • To evaluate the prognostic and therapeutic implications of post-CCT PAC in PA patients.

Main Methods:

  • Retrospective analysis of 540 PA patients with complete CCT and echocardiographic data.
  • Assessment of clinical and echocardiographic parameters at baseline and 1 year post-treatment.
  • Statistical analyses including restricted cubic spline and linear regression.

Main Results:

  • Post-CCT PAC showed a significant linear association with left ventricular mass index (LVMI) and E/e', indicating a continuum of risk.
  • Post-CCT PAC was associated with baseline LVMI, E/e', and left atrial volume index (LAVI).
  • Higher post-CCT PAC correlated with greater improvements in LVMI, E/e', and LAVI after treatment, unlike baseline aldosterone levels.

Conclusions:

  • Higher post-CCT PAC is linked to more severe left ventricular remodeling and diastolic dysfunction.
  • Post-CCT PAC predicts the severity of cardiac disease in PA patients.
  • Elevated post-CCT PAC also indicates greater potential for cardiac structure and function improvement after PA-targeted treatment.